New T Cell Engagers Target Hidden Cancer Proteins
Preclinical candidates from T-Cypher Bio aim at peptides antibodies cannot reach, with clinical trials projected for 2028.
Updated on Nov. 3, 2026 in Biotech
T-Cypher Bio, a biotechnology company developing TCR-based T cell engagers, presented preclinical data on two candidates at the 2026 SITC annual meeting in Phoenix, Arizona. The candidates, TC11 and TC25, are research-stage and remain in IND-enabling studies, with clinical trial entry projected for 2028.
Why it matters
Most cancer-specific proteins sit inside cells, where antibodies and antibody-based T cell engagers cannot reach them, which has limited the target pool for this class of therapy. T-Cypher's approach targets peptides presented on the cell surface, aiming to widen that pool as the field pushes toward cell-based cancer treatments.
The company's T-Cα platform is a closed-loop, wet-lab and AI-enabled discovery engine that scans healthy and diseased tissue to identify targets expressed at sufficient peptide copy levels. The poster data are preclinical; no efficacy or safety figures from the source are reported.
The players
T-Cypher Bio
A biotechnology company, based in Oxfordshire, United Kingdom, developing TCR-based T cell engagers with its T-Cα discovery engine and T-Synapse bispecific format.
SITC
The Society for Immunotherapy of Cancer, whose 2026 annual meeting in Phoenix, Arizona hosted the presentations.
The details
T cell engagers are bispecific molecules that bring a patient's T cells, the immune system's killer cells, into contact with tumor cells. T-Cypher uses TCR-based recognition, which lets the engager target short peptide fragments displayed on the cell surface rather than whole proteins buried inside the cell. Its T-Cα platform scans tissue samples to find these peptides at high enough copy numbers to serve as targets, and that target bank fed the design of the T-Synapse bispecific format, which includes an extended in vivo half-life and a safety-tailored anti-CD3 arm.
Timeline
November 6, 2026: TC11 poster presented at SITC as Abstract #891.
November 7, 2026: TC25 poster presented at SITC as Abstract #894.
2028: Both candidates projected to enter clinical trials.
The Tech Race
T-Cypher's TC11 and TC25 candidates are preclinical entrants in a field where bispecific T cell engagers are advancing toward the clinic. The company's emphasis on peptide-based TCR targeting positions it against antibody-based engagers that cannot reach intracellular proteins.
These candidates are not yet available to patients and are still in preclinical development, so no near-term treatment access is implied. Patients with melanoma, lung, head and neck, or gastrointestinal tumors would only see a practical effect if the candidates advance through clinical trials starting around 2028.
The takeaway
The key trajectory is whether peptide-based TCR targeting can reach the large share of cancer proteins that antibody engagers miss. Watch for the 2028 clinical trial entry of TC11 and TC25 as the first test of that approach in patients.
What happens next
Both TC11 and TC25 are projected to enter clinical trials in 2028, the next milestone to track.
Further reading
For broader context on how immune-based cancer treatments are being developed, explore Biotech coverage.
Source note: This article includes information reported by The Manila times.
